Yazar "Ozcan, Seyda Gul" seçeneğine göre listele
Listeleniyor 1 - 7 / 7
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe A comparison of antibody response in kidney transplant recipients and healthcare workers who had PCR-confirmed COVID-19 infection(Tubitak Scientific & Technological Research Council Turkey, 2022) Dincer, Mevlut Tamer; Eren, Necmi; Murt, Ahmet; Yildiz, Nuriye; Ozcan, Seyda Gul; Ergul, Metin; Bek, Sibel GokcayBackground/aim: Data on antibody response following COVID-19 in kidney transplant recipients is scarce. This crosssectional study aims to investigate the antibody response to COVID-19 among kidney transplant recipients. Materials and methods: We recruited 46 kidney transplant recipients with RT-PCR-confirmed COVID-19 and 45 recipients without COVID-19 history. We also constructed two control groups (COVID-19 positive and negative) from a historical cohort of healthcare workers. We used age and sex-based propensity score matching to select the eligible subjects to the control groups. We measured the SARS-CoV-2 IgG levels quantitatively using the Abbott ARCHITECT system. An antibody level above 1.4 S/C was defined as positivity. Results: Transplant recipients with COVID-19 had a higher BMI, and COVID-19 history in a household member was more common than that of the transplant recipient without COVID-19. IgG seropositivity rate (69.6% vs. 78.3%, p = 0.238) and the median IgG level (3.28 [IQR: 0.80-5.85] vs. 4.59 [IQR: 1.61-6.06], p = 0.499) were similar in COVID-19-positive transplant recipients and controls. Kidney transplant recipients who had a longer duration between RT-PCR and antibody testing had lower antibody levels (r = -0.532, p < 0.001). Conclusion: At the early post-COVID-19 period, kidney transplant recipients have a similar antibody response to controls. However, these patients' antibody levels and immunity should be closely monitored in the long term.Öğe ASSOCIATION OF MULTIPLE PLASMA BIOMARKER LEVELS WITH KIDNEY DISEASE ACTIVITY IN FABRY DISEASE(Oxford Univ Press, 2023) Ozcan, Seyda Gul; Atli, Zeynep; Eren, Necmi; Dincer, Mevlut Tamer; Turkmen, Kultigin; Ozer, Hakan; Trabulus, Sinan[No abstract available]Öğe Coronary artery calcification progression and long-term cardiovascular outcomes in renal transplant recipients: an analysis by the joint model(Oxford Univ Press, 2022) Seyahi, Nurhan; Alagoz, Selma; Atli, Zeynep; Ozcan, Seyda Gul; Tripepi, Giovanni; Bakir, Alev; Trabulus, SinanBackground. Compared with the general population, the risk of death is substantially higher in renal transplant recipients than in age- and sex-matched individuals in the general population. In the general population, coronary artery calcification (CAC) predicts all-cause and cardiovascular mortality. In this study we aimed to analyse these relationships in renal transplant recipients. Methods. We examined 178 renal transplant patients in this prospective observational cohort study. We measured CAC with multidetector spiral computed tomography using the Agatston score at multiple time points. Overall, 411 scans were performed in 178 patients over an average 12.8 years follow-up. The clinical endpoint was a composite including all-cause death and non-fatal cardiovascular events. Data analysis was performed by the joint model. Results. During a follow-up of 12.862.4 years, coronary calcification progressed over time (P < 0.001) and the clinical endpoint occurred in 54 patients. In the analysis by the joint model, both the baseline CAC score and the CAC score progression were strongly associated with the incidence rate of the composite event [hazard ratio 1.261 (95% confidence interval 1.119-1.420), P = 0.0001]. [GRAPHICS] Conclusions. CAC at baseline and coronary calcification progression robustly predict the risk of death and cardiovascular events in renal transplant recipients. These findings support the hypothesis that the link between the calcifying arteriopathy of renal transplant patients and clinical end points in these patients is causal in nature.Öğe DEVELOPMENT AND VALIDATION OF THE THIRST DISTRESS SCALE FOR PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE(Oxford Univ Press, 2022) Ozcan, Seyda Gul; Bek, Sibel; Eren, Necmi; Atli, Zeynep; Yildiz, Abdulmecit; Kocyigit, Ismail; Cavdar, Caner[No abstract available]Öğe Effects of Antithymocyte Globulin, Basiliximab, and Induction-Free Treatment in Living Donor Kidney Transplant Recipients on Tacrolimus-Based Immunosuppression(Baskent Univ, 2024) Sonmez, Ozge; Ozcan, Seyda Gul; Karaca, Cebrail; Atli, Zeynep; Dincer, Mevlut Tamer; Trabulus, Sinan; Seyahi, NurhanObjectives: Induction treatment in renal transplant is associated with better graft survival. However, intensified immunosuppression is known to cause unwanted side effects such as infection and malignancy. Furthermore, the effects of the routine use of immunosuppressants in low -risk kidney transplant recipients are still not clear. In this study, we assessed the first -year safety and efficacy of induction treatment. Materials and Methods: We examined first living donor kidney transplant patients who were on tacrolimusbased immunosuppression therapy. We formed 3 groups according to the induction status: antithymocyte globulin induction, basiliximab induction, and no induction. We collected outcome data on delayed graft function, graft loss, creatinine levels, estimated glomerular filtration rates, acute rejection episodes, hospitalization episodes, and infection episodes, including cytomegalovirus infection and bacterial infections. Results: We examined a total of 126 patients (age 35 +/- 12 years; 65% male). Of them, 25 received antithymocyte globulin, 52 received basiliximab, and 49 did not receive any induction treatment. We did not observe any statistically significant difference among the 3 groups in terms of acute rejection episodes, delayed graft function, and first -year graft loss. The estimated glomerular filtration rates were similar among the groups. Overall bacterial infectious complications and cytomegalovirus infection showed similar prevalence among all groups. Hospitalization was less common in the induction -free group. Conclusions: In low -risk patients, induction -free regimens could be associated with a better safety profile without compromising graft survival. Therefore, induction treatment may be disregarded in first living donor transplant patients who receive tacrolimusbased triple immunosuppression treatment.Öğe Sarcopenia, an overlooked diagnosis in kidney transplant recipients(Dustri-Verlag Dr Karl Feistle, 2024) Ozcan, Seyda Gul; Sonmez, Ozge; Atli, Zeynep; Karaca, Cebrail; Alagoz, Selma; Akman, Zafer; Koroglu, Ali EgemenMost studies of sarcopenia in renal transplant recipients (RTRs) have been hampered by a lack of standardization in the definitions of sarcopenia. In this study, we aimed to investigate the prevalence of sarcopenia and the associated factors in RTRs using the recently proposed criteria of the European Working Group on Sarcopenia in Older People 2018 (EWGSOP2), which included a standardized definition of sarcopenia. We examined 93 consecutive adult RTRs, 46 chronic kidney disease patients, and 46 healthy controls. We assessed the muscle strength with a hand grip test using a dynamometer and with a chair stand test. We used bioimpedance analysis to estimate appendicular skeletal mass using the Sergi formula. Finally, we conducted a 2-minute walking test to assess endurance. Sarcopenia and probable sarcopenia were determined according to the revised criteria of the EWGSOP2. Probable sarcopenia was found in 29 RTR patients (31.2%), of them 14 (15.1%) were diagnosed with sarcopenia. Multivariate logistic regression analysis showed that presence of diabetes mellitus, increased uric acid level, and statin use were risk factors for probable sarcopenia. On the other hand, longer dialysis vintage was a risk factor for sarcopenia in RTRs. We found that probable sarcopenia and sarcopenia were highly prevalent in our relatively young RTRs. We recommend active screening for the presence of sarcopenia in RTRs, especially in the cadaveric ones. Furthermore, caution seems warranted regarding the myopathic side effects in RTRs who use statins.Öğe SARCOPENIA: AN OVERLOOKED DIAGNOSIS IN KIDNEY TRANSPLANT RECIPIENTS(Oxford Univ Press, 2022) Ozcan, Seyda Gul; Sonmez, Ozge; Akman, Zafer; Karaca, Cebrail; Atli, Zeynep; Trabulus, Sinan; Seyahi, Nurhan[No abstract available]
